This study focuses on patients with Small Cell Lung Cancer (SCLC), an aggressive form of lung cancer. The research evaluates a medication called tarlatamab (also known as AMG 757), which is given through an intravenous infusion. The medication is provided as a powder that is mixed into a solution before administration into a vein.

The purpose of this research is to test different dosing schedules of tarlatamab to determine how well it works in treating Small Cell Lung Cancer. The study will include patients whose cancer has continued to grow or has returned after receiving previous treatment with platinum-based chemotherapy. Some patients may have also received prior treatment with other cancer medications.

During the study, participants will receive tarlatamab through regular intravenous infusions. Another medication called siltuximab may also be used as part of the treatment plan. Patients will have regular check-ups and tests to monitor their health and how their cancer responds to the treatment. The study team will track various aspects of the treatment’s effectiveness, including how the cancer responds and how long these responses last.